Dr. Falk Pharma and Renexxion announce positive results on naronapride in gastroparesis from the global phase 2b MOVE-IT trial
May 4, 2026
MOVE-IT met the primary endpoint with statistically significant improvement in gastroparesis symptoms in 20 mg